Business Wire

CO-BONA

18.3.2024 09:06:33 CET | Business Wire | Press release

Share
Bona Pet System™ and Bona OxyPower Products Receive Environmental Protection Agency Safer Choice Certification

Today, Bona® announced that four of its products are now certified by the U.S. Environmental Protection Agency (EPA) Safer Choice program and have earned the Safer Choice label. The new certification applies to the Bona Pet System™ including Bona Pet System™ Hard-Surface Floor Deep Cleaner and Bona Pet System™ Wood Floor Deep Cleaner as well as Bona’s OxyPower floor cleaners -- Bona OxyPower Hard-Surface Floor Deep Cleaner and Bona OxyPower Wood Floor Deep Cleaner. Safer Choice is a voluntary EPA program that certifies cleaning and other products made with ingredients that are safer for people, pets, and the planet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318768884/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bona Pet System™ and Bona OxyPower Products Receive Environmental Protection Agency Safer Choice Certification (Graphic: Business Wire)

“As we continue our journey to innovate cleaning solutions that bring out the beauty in floors, our primary focus is to leverage the latest technologies and research when it comes to ingredients,” said Marie Shore, Director Product Management EMEA & APAC, Bona.“Recognition like this one from the EPA Safer Choice program is a key milestone in validating our work for a more sustainable future.”

The Safer Choice label is a reliable way to find products made with safer ingredients without sacrificing performance. Every ingredient in products that carry the Safer Choice label is reviewed by EPA scientists to make sure certified products only contain the safest possible ingredients for people and the planet. Safer Choice-certified products are made with ingredients that won't cause serious health problems, like cancer, and aren't harmful to fish or waterways. Safer Choice also restricts volatile organic compounds to minimize indoor air pollution and associated respiratory concerns. Products with the label also use more sustainable packaging that doesn't contain toxic chemicals, like heavy metals.

Powered by hydrogen peroxide, Bona OxyPower Wood Floor Deep Cleaner and Bona OxyPower Hard-Surface Floor Deep Cleaner are specifically designed to remove heavy dirt build-up, providing a deep clean for wood or hard-surface floors. The ready-to-use, oxygenated, waterbased formula releases thousands of micro-bubbles that loosen heavy dirt build-up, removes stuck-on messes, and lifts away stains via a bubbling action to provide a deep clean for floors.

Formulated specifically for cleaning pet messes, The Bona Pet System Hard Surface Floor Deep Cleaner and Bona Pet System Wood Floor Deep Cleaner offer a deep clean by penetrating through tough stuck-on stains, tracked in dirt, and accident messes with the cleaning power of Hydrogen Peroxide. The Odour Guard Technology™ eliminates and neutralizes urine and other organic odours upon contact.

For more information about Bona Pet System and OxyPower cleaners are visit www.bona.com. These GREENGUARD certified products are available in EMEA and APAC regions.

“These four cleaning products were developed to meet the high standards of consumers as well as certifying organizations like the EPA Safer Choice program,” continued Shore. “With 11 Safer Choice certified products in North America it made sense to seek this certification for our products in Europe. It all aligns to our long-standing mission to minimize our environmental impact by innovating safer systems and products to the highest sustainability standards.”

About the EPA Safer Choice Program

Safer Choice incentivizes safer, greener chemistry by allowing companies to differentiate their products in the marketplace with the Safer Choice label. With thousands of certified products, the Safer Choice label is a reliable way to find products made with safer ingredients without sacrificing performance. For more information about the Safer Choice program, visit: www.epa.gov/saferchoice.

About Bona®

Bona® is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. Bona’s turnover is 4.1bn SEK (EUR 366million) 2023. The head office is in Malmö, Sweden, and the company is represented globally by its 17 subsidiaries, 70 distributors, 4 production sites and over 600 employees. For more visit www.bona.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240318768884/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye